Non-Sponsored Content
Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated metastatic colorectal cancer
By: News Feed | Last updated: 11th July 2018 | In: Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals
Article Keywords
BMS, Bristol-Myers Squibb, dMMR, FDA, fluoropyrimidine, fluorouracil, ipilimumab, irinotecan, MSI-H, nivolumab, Opdivo, oxaliplatin, Yervoy
On July 10th, the FDA granted accelerated approval to ipilimumab (Yervoy©, Bristol-Myers Squibb) for use in combination with nivolumab (Opdivo©) for the treatment of adult and paediatric patients ≥12 years of age with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. More Information.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2018 MediPaper Medical Communications Ltd.
Trackbacks & Pingbacks
[…] Only in combination with nivolumab; […]
[…] ©United States Food and Drug AgencyJuly 11, 2018/by News Feed […]
Leave a Reply
Want to join the discussion?Feel free to contribute!